

Melphalan, Antimelanoma Immunity, and Inflammation—Letter

Anna Martner¹, Junko Johansson¹, Ilan Ben-Shabat², and Roger Olofsson Bagge²

The recent study by Dudek-Perić and colleagues aimed at delineating immunogenic properties of melphalan, with focus on its use in isolated limb perfusion (Mel-ILP) in metastatic melanoma (1). The authors demonstrated that mice vaccinated with melphalan-treated melanoma cells were protected from challenge with viable melanoma cells *in vivo* in a CD8⁺ T-cell-

with in-transit melanoma metastases, as described in a previous pilot study (2). We observed that patients who achieved a complete response (CR) after Mel-ILP, i.e., a complete disappearance of macroscopic tumors, showed higher counts of CD3⁺CD8⁺CD45RA⁺ T cells and of activated CD3⁺HLADR⁺ T cells than those not achieving CR (Fig. 1A). The levels of CD3⁺CD8⁺




Figure 1.

The absolute counts of subpopulations of T cells (A) and the ratio of CD3⁺8⁺RA⁺/CD3⁺8⁺RO⁺ T cells (B) in peripheral blood before treatment with melphalan-based isolated limb perfusion were analyzed as predictive factors for the clinical response evaluated at 3 months after perfusion ($n = 43$ for CD3⁺8⁺ cells, $n = 38$ for the other subgroups and for the ratio of CD3⁺8⁺RA⁺/CD3⁺8⁺RO⁺ T cells). P values were calculated using the Mann-Whitney test. CR, complete response; No CR, no complete response.

dependent manner (1). However, it remains to be clarified whether Mel-ILP triggers T-cell-dependent regression of melanoma also in humans. We asked whether the patients' T-cell phenotypes in blood prior to Mel-ILP might herald efficiency of response. Thus, the absolute counts of peripheral blood CD8⁺ T cells and their expression of activation markers immediately prior to Mel-ILP were assessed by flow cytometry in 43 patients

CD45RA⁺ T cells remained significantly associated with CR also after correction for multiple analyses using the Bonferroni method. We also noted that patients achieving CR had significantly higher ratios of CD8⁺CD45RA⁺/CD8⁺CD45RO⁺ T cells in blood ($P = 0.004$, Mann-Whitney test; Fig. 1B). Fifteen of 19 patients achieving CR had a CD8⁺CD45RA⁺/CD8⁺CD45RO⁺ ratio above 1 versus 6 of 19 patients not achieving CR ($P = 0.008$, Fisher exact test). As CD45RA is expressed by naïve as well as by effector T cells, further studies are needed to define which subpopulation of T cells correlates to melphalan responsiveness. Our results, which should be validated in larger studies, provide indirect support to the concept of immunogenic cell death after Mel-ILP in human melanoma and point toward CD8⁺ T cells as a relevant effector cell population.

¹Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden. ²Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.

Corresponding Author: Roger Olofsson Bagge, Sahlgrenska University Hospital, Bla Straket 5, Gothenburg 40320, Sweden. Phone: 46-31-3428207; Fax: 46-31-3420000; E-mail: roger.olofsson@surgery.gu.se

doi: 10.1158/0008-5472.CAN-15-1184

©2015 American Association for Cancer Research.

Received May 1, 2015; revised May 27, 2015; accepted May 30, 2015; published OnlineFirst December 1, 2015.

References

1. Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. *Cancer Res* 2015;75:1603–14.
2. Olofsson R, Lindberg E, Karlsson-Parra A, Lindner P, Mattsson J, Andersson B. Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. *Int J Hyperthermia* 2013;29:234–8.